CRISPR Therapeutics AG (LON: 0VRQ)

Market Cap	3.06B
Revenue (ttm)	151.33M
Net Income (ttm)	-178.76M
Shares Out	n/a
EPS (ttm)	-2.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,856
Average Volume	7,629
Open	42.00
Previous Close	42.09
Day's Range	41.26 - 42.41
52-Week Range	31.29 - 72.28
Beta	n/a
RSI	48.73
Earnings Date	Feb 21, 2025

About CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company’s lead product cand...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 407
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0VRQ

Financial Performance

In 2023, CRISPR Therapeutics AG's revenue was $371.21 million, an increase of 30885.48% compared to the previous year's $1.20 million. Losses were -$153.61 million, -76.37% less than in 2022.

Financial numbers in USD